Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
About this study
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
- Condition
- Acute Myeloblastic Leukemia
- Tested
- Epigenetic markers
- Sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Who can join
- Age
- 60 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 9
- Minimum age: 60 years
- Study condition: Acute Myeloblastic Leukemia
- / Control Group
- Age ≥ 60 years;
- Scheduled for cardiac surgery involving sternotomy;
- Normal blood count within the two months preceding sampling;
- Affiliated with, or beneficiary of, a social security system;
- Written informed consent to participate in the study.
- Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;
Exclusion 12
- Patients deemed unsuitable for sampling by the surgeon performing the procedure;
- Patients under legal protection measures;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision;
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).
- / AML Group
- Diagnosis of a hematologic disease other than AML;
- Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;
- Previous treatment for AML other than hydroxyurea;
- Severe comorbidities that could interfere with the study, as assessed by the principal investigator;
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);
- Patients under legal protection;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision.
Where
2 sites, 2 recruiting
Groupe Hospitalier de la Région de Mulhouse et Sud Alsace
Mulhouse, Alsace, France
GHRMSA
Mulhouse, France
Contact
-
Bernard DRENOU, Dr
+33389646464 drenoub@ghrmsa.fr
Potential match only. Final eligibility is determined by the study team.